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Bisphosphonates are drugs indicated for the treatment of bone metabolic diseases or malignant hypercalcemia. 
They are generally well-tolerated drugs, however, recent reports have described osteonecrosis of the jaw bones 
as a potentially serious complication related to the long-term use of these drugs. We report a case of severe os-
teonecrosis in a 52-years-old white woman that was taking bisphosphonates (zoledronic acid and alendronate) for 
the management of osteoporosis. Following a long exposure to these drugs and after being subjected to multiples 
exodontias, developed bisphosphonate-related osteonecrosis of the jaw compromising the whole maxilla and that 
extended toward the base of skull. Due to the extent of osteonecrosis, total maxillectomy and removal of all ad-
jacent necrotic bone were planned guided by ultraviolet light. fluorescence. This case illustrates that if not treated 
correctly, bisphosphonate-related osteonecrosis of the jaw may cause significant morbidity, affect the quality of life 
and can eventually produce significant morbidity with the dissemination to noble structures and potentially causing 
life-threatening complications.





Bisphosphonates are medications indicated for the 
treatment of bones metabolic diseases, including os-
teoporosis, osteogenesis imperfecta, Paget disease or 
for management of malignant hypercalcemia, such as 
those associated with multiple myeloma; cervical, lung 
or mammary cancer. They are generally a well-tolerated 
drugs, causing few side effects, such as gastrointestinal 
symptoms, transient low grade fever, arthralgias and in-
creased bone pain for the injectable drugs. In addition, 
elevated serum levels of creatinine have been observed 
in some cases. However, recent reports have described 
osteonecrosis of the jaw bones as a potentially serious 
complication associated with the long-term use of these 
drugs (1).
This complication is more frequent in women than in 
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men and the mean age is 66 years. The incidence of 
BRONJ is higher in the mandible than in the maxilla, 
with a 2:1 ratio (2). The criteria for the diagnosis of 
BRONJ include: 1 - current or previous treatment with 
antiresorptive or antiogenic agents; 2 - exposed bone or 
bone that can be probed through intra or extra oral fistu-
la in the maxillofacial region persisting for more than 8 
weeks; and 3 - no history of radiation therapy to the jaw 
(3). The staging of the disease is based on severity of 
symptoms and extension of the clinical and radiographic 
findings. The main objective of the treatment of BRONJ 
is to preserve the quality of life, controlling pain and 
infections and to prevent the development of new areas 
of necrosis (4). Treatment strategies range from conser-
vative local wound care to aggressive resective surgery 
of all necrotic bones (2). Conservative strategies inclu-
de systemic antibiotics, oral antibacterial rinse, and de-
bridement of loose necrotic bone. Recent studies have 
demonstrated to be promising the use of non-surgical 
therapeutic strategies such as platelet rich plasma (5), 
parathyroid hormone (6), hyperbaric chamber (7). 
The aim of the present study is to present an atypical 
case of BRONJ that, due to its severity it was necessary 
to perform total maxilectomy.
Case Report 
A was 52-years-old white woman with history of hyper-
tension, diabetes, rheumatoid arthritis treated with 
corticoid (prednisone 10mg/day) was evaluated in our 
department with complains of recurrent infections and 
maxillary bone exposure. The patient reported that from 
2007 started treatment for osteoporosis with zoledronic 
acid (5mg/month) that was replaced after five years by 
oral alendronate sodium (70mg / week). In 2013 un-
derwent multiple exodontias and after 10 months deve-
loped persistent pain, recurrent infections and bone ex-
posure at the sites of extractions. The patient was treated 
with multiple antibiotics and curettage by her general 
dental practitioner.  In 2016, after worsening of the con-
dition, she was referred to the Department of Oral and 
Maxillofacial Surgery of Universitary Hospital (Federal 
University of Paraiba, Brazil).
The clinical examination revealed edema and erythema 
in the third middle of the face, total maxillary edentu-
lism, presence of necrotic bone exposure involving an 
extensive area of the maxilla associated with dehiscen-
ce in the alveolar and palatine mucosa on the left side 
and minor points on the right side (Fig. 1A,B) which 
was notorious for its fetid odor and spontaneous puru-
lent drainage. A CT-scan revealed necrotic bone widen 
throughout all maxilla and the left pterygoid process ex-
tending the proximity of skull base. A three-dimensional 
reconstruction view allowed clear visualization of the 
separation line at the Le Fort I level (Fig. 1 C,D). 
The initial management included treatment for infection 
and the acute pain. The patient was given Amoxicillin 
Fig. 1: A: Intra oral clinical picture of extensive exposed necrotic bone. B: Palatine view show-
ing exposed necrotic bone. C: Three-dimensional reconstruction CT-scan showing necrotic area 
compromising the whole maxilla. D: Coronal bone window image showing necrotic bone extended 
toward the skull base 
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500mg plus Clavulanic Acid 125mg and Paracetamol 
500mg as well as mouthwash (chlorhexidine digluco-
nate 0.12%). Subsequently, due to the extent of osteo-
necrosis, total maxillectomy and removal of all adja-
cent necrotic bone were planned. Bone resection was 
guided by ultraviolet light fluorescence through the use 
of 100mg doxycycline twice daily for 10 days prior to 
surgery (Fig. 2A-C). In the immediate postoperative pe-
riod, the patient was fed by nasal enteral tube to avoid 
food residues at the surgery site. In addition, smeared 
gauze with antibiotic ointment (bacitracin and neomy-
cin) changed daily in the first seven days was utilized. 
Antibiotic therapy was maintained until 10 days after 
surgery and treatment with Tocopherol (500 mg, twice 
a day) and Pentoxifylline (400 mg, twice a day) was 
started aiming at reducing fibrosis and stimulating local 
vascularization for a period of eight months.
After a period of Six-months, complete tissue healing 
was observed (Fig. 2D,E) Postoperative CT-scan perfor-
med six-months after the first surgery revealed satisfac-
Fig. 2: A: Clinical pictures of transoperative after removal necrotic bone. B: Fluorescence view after removal necrotic bone. C: Suture of 
the residual soft tissue. D: Six-months postoperative intra oral clinical picture. E: Palatine view showing  oro-antral comunication. F: sex 
months postoperative three-dimensional reconstruction CT- scan showing absence of necrotic bone. G: six months postoperative Coronal 
bone window view.
tory healing of the remaining bone (Fig. 2F,G) and then 
closure of the oro-antral communications left by bone 
resection was realized, as there was not sufficient tissue 
for primary closure. Closing was performed in three la-
yers (Fig. 3A). The first layer consisted of the surroun-
ding oral mucosa to form the floor of the maxillary si-
nus, followed by a layer of the buccal fat pad as pedicled 
graft and covered as a tunneling myomucosal flap from 
the buccinator muscle (Fig. 3B-F). Currently, the patient 
is without pain nor signs of relapse. 
Discussion
BRONJ most commonly affects women, due to cases 
involving treatments for breast cancer and osteoporosis 
and the mean age is 68 years (3,8). The risk of deve-
loping BRONJ is greater with the use of intravenous 
bisphosphonates in cancer patients, the most common 
malignant diseases are breast cancer and  multiple mye-
loma, and was first reported with use of zoledronic acid 
and disodium paminodrate, however, oral bisphospho-
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Fig. 3: A: The drawing illustrating the sequence of the closure of oro-antral communication in three layers: the surround-
ing oral mucosa to form the floor of the maxillary sinus, buccal fat pad as pedicled graft and myomucosal flap from the 
buccinator muscle. B: Bucal fat pad as pedicled graft used to close oro-antral comunication. C: Myomucosal flap drawing
D: Appearance after tunneling myomucosal flap from the buccinator muscle suture . E: Immediately postoperative clini-
cal appearance. F: Twelve months postoperative showing absence of oro-antral communication and exposed bone.
nates for the treatment of osteoporosis can also cause 
BRONJ. Despite the lower incidence, the number of ca-
ses is significant and probably underestimated (3,8,9). 
Our patient was female and used intravenous zoledronic 
acid monthly for five years due osteoporosis and was 
subsequently replaced with oral alendronate.
BRONJ can be misdiagnosed as alveolar osteitis, sinusitis, 
gingivitis / periodontitis, periapical pathologies, fibro-os-
seous lesion, sarcoma and chronic sclerosing osteomyeli-
tis (3). In this case, the patient remained on non-effective 
treatments for two years, probably being treated wrongly 
as some of these conditions. The delay in providing ti-
mely and proper treatment led to the need of performing 
total maxillectomy causing high morbidity.
There are rare cases of spontaneous development 
BRONJ, most cases affect patients who underwent 
dentoalveolar surgeries. Therefore, patients and prac-
titioners should be advised about the relation of treat-
ment with bisphosphonates and the risk of developing 
BRONJ. Patients who will start bisphosphonate treat-
ment, if medical conditions allow it, should delay the 
treatment until oral health is optimized to minimize the 
risks of developing BRONJ, this decision must be made 
together with the patient´s physician (10).
The incidence of BRONJ depends on the type of me-
dication used, duration of administration, and medical 
conditions such as the presence of systemic diseases, 
associated medication and local lesions. The patient in 
this report had multiple systemic diseases such as dia-
betes mellitus, rheumatoid arthritis and was also using 
corticosteroids and various studies have reported that the 
use of corticosteroids, immunosuppressive therapies and 
diabetes mellitus are considered important risk factors 
for the development of this complication (11).
The extent of bone resection, in most cases, is subjective 
and depends on the transoperative parameters. Charac-
teristics that do not correlate with bone vitality, such as 
coloration, bone bleeding and others, are observed. As a 
way to allow surgical standardization, fluorescence-gui-
ded bone resection has emerged and is a technique that 
allows the surgeon to distinguish between viable and ne-
crotic bone, so there is no other technique that allows 
visualization of residual necrotic bone (12). The fluores-
cence technique to guide the bone resection was effec-
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tive in this case, because it allowed the total removal of 
the necrotic bone tissue, as it can be visualized on the 
postoperative CT-scan.
In the case presented here, due to dehiscence caused by 
osteonecrosis and cicatricial retraction, the patient deve-
lops oro-antral communications. A treatment plan was 
established with the use of three layers: 1 - Surrounding 
oral mucosa; 2 - Buccal fat pad as pedicled graft and 3 
- Myomucosal tunneling flap from the buccinator mus-
cle. The buccal fat pad has been proved to be a low risk 
approach and is associated with high success rate, inclu-
ding for the closing of large oral communications like 
this one (13). Furthermore, the myomucosal buccinators 
flap are also an excellent option to reconstruc palatal de-
fects, these are functionally and aesthetically good, with 
few failures and low morbidity at the donor site (14).
Pentoxifylline and Tocopherol were used in this case in 
order to improve vascularization, accelerate healing and 
to avoid fibrosis of adjacent soft tissues. Pentoxifylline 
is used in the management of vascular diseases, such as 
ischemic heart disease and intermittent claudication, im-
proves peripheral blood flow, increasing flexibility and 
vasodilation of erythrocytes. It also inhibits tumor ne-
crosis factor alpha and may decrease inflammatory reac-
tions and fibrosis. It is also very likely to have an effect 
on the decrease of pain and the acceleration of scarring 
of radiation-induced soft tissue necrosis. Tocopherol 
reduces oxygen free radicals, its antioxidant properties 
occur through the inhibition of platelet aggregation and 
also reduces tissue fibrosis. The combination of these 
two medications is well tolerated and has shown efficacy 
in the treatment of BRONJ (15).
Conclusions
We report an atypical case of BRONJ extending across 
the maxilla and getting close to skull base. If not treated 
correctly, this pathology can evolve severely to affect 
the quality of life and can eventually produce significant 
morbidity with the dissemination to noble structures and 
potentially causing life-threatening complications. 
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